These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Editorial: in vino veritas-- transient elastography for staging liver fibrosis in alcoholic liver disease. Thiele M; Krag A Aliment Pharmacol Ther; 2016 May; 43(9):1014-5. PubMed ID: 27040164 [No Abstract] [Full Text] [Related]
7. Editorial: in vino veritas--transient elastography for staging liver fibrosis in alcoholic liver disease--authors' reply. Pavlov C; Casazza G; Nikolova D; Gluud C Aliment Pharmacol Ther; 2016 May; 43(9):1015-6. PubMed ID: 27040165 [No Abstract] [Full Text] [Related]
8. Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice? Neil Guha I; Patel K Aliment Pharmacol Ther; 2020 Jan; 51(1):179-180. PubMed ID: 31850556 [No Abstract] [Full Text] [Related]
9. Editorial: stepwise risk stratification for both F3 and F4 fibrosis stage in NAFLD patients. Idriss R; Lai M Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1317-1318. PubMed ID: 30488626 [No Abstract] [Full Text] [Related]
10. Editorial: the impact of steatosis on liver stiffness quantification is minimal-Authors' reply. Karlas T; Petroff D; Wiegand J Aliment Pharmacol Ther; 2018 May; 47(10):1417-1418. PubMed ID: 29676009 [No Abstract] [Full Text] [Related]
11. Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes. Fan W; Torok NJ Hepatol Commun; 2021 Apr; 5(4):553-555. PubMed ID: 33860113 [TBL] [Abstract][Full Text] [Related]
12. Myocardial Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the Liver-Heart Axis. Isaak A; Praktiknjo M; Jansen C; Faron A; Sprinkart AM; Pieper CC; Chang J; Fimmers R; Meyer C; Dabir D; Thomas D; Trebicka J; Attenberger U; Kuetting D; Luetkens JA Radiology; 2020 Oct; 297(1):51-61. PubMed ID: 32808886 [TBL] [Abstract][Full Text] [Related]
13. Histopathological evaluation of liver fibrosis and cirrhosis regression. Lo RC; Kim H Clin Mol Hepatol; 2017 Dec; 23(4):302-307. PubMed ID: 29281870 [TBL] [Abstract][Full Text] [Related]
14. [Present situation on non-invasive assessment of liver fibrosis/cirrhosis]. Zhang QD; Lu LG Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):325-327. PubMed ID: 29996197 [TBL] [Abstract][Full Text] [Related]
15. Studies on cirrhosis of the liver. IV. The relations between the mortality from liver cirrhosis and the mortality from alcoholism, and between the mortality from liver cirrhosis and alcoholic consumption. NAKAMURA T; NAKAMURA S; KAWAMURA E; KANEKO T; SUGAWARA K; KATAKURA Y; ISONO T; SUZUKI I Tohoku J Exp Med; 1958 Apr; 67(4):365-71. PubMed ID: 13581054 [No Abstract] [Full Text] [Related]
16. Editorial: Advances in Liver Inflammation and Fibrosis Due to Infectious Diseases. Oliveira SC; Delpino MV; Giambartolomei GH; Quarleri J; Splitter G Front Immunol; 2020; 11():1760. PubMed ID: 32849629 [No Abstract] [Full Text] [Related]
17. Editorial: can quantitative fibrosis assessment be used to enhance prediction of outcomes in patients with alcohol-related liver disease? Authors' reply. Israelsen M; Guerrero Misas M; Tsochatzis EA Aliment Pharmacol Ther; 2021 Jan; 53(1):185-186. PubMed ID: 33333595 [No Abstract] [Full Text] [Related]
18. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Stine JG; Rinella ME Am J Gastroenterol; 2017 May; 112(5):752-754. PubMed ID: 28469217 [TBL] [Abstract][Full Text] [Related]